The positive safety results show that the experimental treatment could become a promising early candidate for a chlamydia vaccine. More: Novel chlamydia vaccine proves safe in early trial Source: News
read moreAlmost seven in 10 people referred to digital schemes took part compared with around half of those offered face-to-face support. More: NHS strengthens Long Term Plan with digital diabetes prevention roll-out Source: News
read moreThe rejection was due to ‘uncertainties in the company’s evidence about the long term health benefits of both medicines in relation to their costs.’ More: SMC rejects Orkambi, accepts four medicines Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals